ReviewCells2019
Fibronectin in Cancer: Friend or Foe.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 1 synthesis or guideline pooled it, 235 citations in OpenAlex.
- Integrated assessment of non-invasive diagnostic tools for bladder cancer: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- TCM-based natural products in type 2 diabetes: a comprehensive review of bioactive compounds and molecular mechanisms.Molecular diversity · 2026Review
- Rapidly progressive pediatric fibronectin glomerulopathy driven by a novel FN1 mutation (p.Thr1917del): implications for early diagnosis and recognition of systemic involvement.Pediatric nephrology (Berlin, Germany) · 2026Review
- Integrated bioinformatics and molecular docking identify novel key genes, pathways, and potential candidate drugs in papillary thyroid carcinoma.Journal, genetic engineering & biotechnology · 2026Article
- Epithelial-Mesenchymal Transition, Immune Response, and Extracellular Matrix Remodelling in Oral Cancer.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Article
- TROP2 promotes bone metastasis of colorectal cancer through interaction with the fibronectin-integrin axis.Cellular and molecular life sciences : CMLS · 2026Article
- Structural architecture of collagen and collagen-fibronectin networks is associated with the invasive behavior of liver cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Article
- Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer.Oncogenesis · 2026Article
- Mechanotherapeutic Potential of Survivin in Glioblastoma.bioRxiv : the preprint server for biology · 2026Article
- The extracellular matrix in inflammation and cancer.Molecular biomedicine · 2026Review
- The Stiff Side of Cancer: How Matrix Mechanics Rewrites Non-Coding RNA Expression Programs.Non-coding RNA · 2026Review
- Pathophysiological Roles of Two Intracellular P-Type ATPases: The Cancer-Associated NaInternational journal of molecular sciences · 2026Review
- Digital spatial profiling identifies features of primary and locoregional metastatic vasculature in triple negative breast cancer.Clinical & experimental metastasis · 2026Article
- Article
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- P-glycoprotein 1 as a shared target for resensitizing drug-resistant tumor cells and preventing fibronectin-driven metastasis.Theranostics · 2026Article
- Investigation of the Immunomodulatory Effect of Quinoline Derivatives with Antitumor Activity.Anti-cancer agents in medicinal chemistry · 2026Article
- Genetic associations link lung cancer liability to brain imaging phenotypes and nominate an FN1-associated tumor-oligodendrocyte program in small-cell lung cancer.Frontiers in oncology · 2026Article
- A novel fibronectin-binding peptide reveals dynamic intermediate structures during matrix assembly.Scientific reports · 2025Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of fibronectin (FN) in tumorigenesis and malignant progression has been highly controversial. Cancerous FN plays a tumor-suppressive role, whereas it is pro-metastatic and associated with poor prognosis. Interestingly, FN matrix deposited in the tumor microenvironments (TMEs) promotes tumor progression but is paradoxically related to a better prognosis. Here, we justify how FN impacts tumor transformation and subsequently metastatic progression. Next, we try to reconcile and rationalize the seemingly conflicting roles of FN in cancer and TMEs. Finally, we propose future perspectives for potential FN-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.